| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8623748 | Seminars in Arthritis and Rheumatism | 2018 | 8 Pages |
Abstract
RA patients could be easily stratified prior to therapeutic intervention with two molecules related to the pathway blocked by tocilizumab. G1 patients, who had the best response to tocilizumab, had the highest level of IL-6 and the lowest level of sIL-6R.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Cesar Diaz-Torne, Maria dels Angels Ortiz, Patricia Moya, Maria Victoria Hernandez, Delia Reina, Ivan Castellvi, Juan Jose De Agustin, Diana de la Fuente, Hector Corominas, Raimon Sanmarti, Carlos Zamora, Elisabet Cantó, Silvia Vidal,